Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Retained Earnings (2022 - 2026)

Kura Oncology has reported Retained Earnings over the past 5 years, most recently at -$1.2 billion for Q1 2026.

  • Quarterly Retained Earnings fell 128171.97% to -$1.2 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.2 billion through Mar 2026, down 128171.97% year-over-year, with the annual reading at -$1.2 billion for FY2025, 31.12% down from the prior year.
  • Retained Earnings was -$1.2 billion for Q1 2026 at Kura Oncology, down from -$1.2 billion in the prior quarter.
  • Over five years, Retained Earnings peaked at $974000.0 in Q1 2025 and troughed at -$1.2 billion in Q1 2026.
  • The 5-year median for Retained Earnings is -$686.9 million (2023), against an average of -$549.8 million.
  • The largest YoY upside for Retained Earnings was 100.13% in 2025 against a maximum downside of 219980.56% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$8.0 million in 2022, then skyrocketed by 84.18% to -$1.3 million in 2023, then tumbled by 70350.2% to -$895.4 million in 2024, then plummeted by 31.12% to -$1.2 billion in 2025, then fell by 6.25% to -$1.2 billion in 2026.
  • Per Business Quant, the three most recent readings for KURA's Retained Earnings are -$1.2 billion (Q1 2026), -$1.2 billion (Q4 2025), and -$1.1 billion (Q3 2025).